Clinical Trial Update: Tyrosine Kinase 2 (TYK2) for GA and CS [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a TYK2-targeted therapy for sarcoidosis and granuloma annulare was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granuloma Annulare
• Sarcoidosis

Drugs mentioned

• TYK2 inhibitor (unspecified)

Snippet

Sponsor: Yale University | Conditions: Sarcoidosis, Granuloma Annulare | Phase 2 | Status: WITHDRAWN